|Quantitative Cell-Based Bioassays for Individual and Combination Immune Checkpoint Immunotherapy Targets|
Zhi-jie Jey Cheng, Jamison Grailer, Pete Stecha, Jun Wang, Jim Hartnett, Frank Fan, and Mei Cong
Immune checkpoint receptors are promising new immunotherapy
targets for the treatment of a variety of diseases including cancer and
autoimmune-mediated disorders. We developed a suite of cell-based
bioluminescent reporter bioassays for individual and combination
immune checkpoint immunotherapy targets including: PD-1 (PD-L1 or PD-L2), CTLA-4, LAG-3, TIGIT, PD-1+TIGIT, GITR, 4-1BB, CD40, and OX40.
|A Novel Set of Serum-Free, Xeno-Free Differentiation Media for Adipogenesis, Osteogenesis and Chondrogenesis of Human Mesenchymal Stem Cells from Various Tissue Sources|
Mira Genser-Nir, Sharon Daniliuc, Marina Tevrovsky, Roni Hazan Brill, Yuliya-Yael Miropolski, David Fiorentini.
An overview of a novel SF, XF differentiation system which enables achieving defined conditions for rapid generation of differentiated hMSCs towards tissue engineering and drug screening applications
|A Synthetic CRISPR-Cas9 System for Homology-directed Repair|
John A. Schiel, Maren M. Gross, Emily M. Anderson*, Eldon T. Chou, Anja van Brabant Smith Dharmacon, part of GE Healthcare, 2650 Crescent Drive, Lafayette, CO 80026, USA
Synthetic, dual-RNA-encoded Cas9 is used for precise homology-directed repair (HDR) gene engineering. Both short and long (GFP) inserts are covered.
|Phenotypic Cell-Based Screening of a High Content Imaging Cell Health Assay using the IN Cell Analyzer 2000|
Zaynab Neetoo-Isseljee, Chido Mpamhanga, David Tickle, Debra Taylor and Janet Brownlees
A High Content Imaging Cell Health assay has been established in-house for phenotypic High Content Screening using the IN Cell Analyzer 2000 and Genedata Screener analysis software. We describe the assay development and initial screening of the FDA set in HepG2 cells for validation of the assay.
|CRISPR-Cas9 genome editing utilizing chemically synthesized RNA|
Kaizhang He, Eldon Chou, Amanda Haas, Žaklina Strezoska, Melissa L. Kelley, and Anja van Brabant Smith Dharmacon, part of GE Healthcare, 2650 Crescent Drive, Lafayette, CO 80026, USA
CRISPR-Cas9 gene editing using synthetic crRNA:tracrRNA or sgRNA is highly efficient and easy to use. Synthetic crRNA:tracrRNA is uniquely suited to in vitro and in vivo applications, in particular, DNA-free approach with Cas9 mRNA. Chemical synthesis of guide RNAs allows accurate and rapid production of arrayed crRNA libraries for high-confidence, loss-of-function screens.
|Advanced Microfluidic Mixing Device for the Study of Macromolecule Dynamics|
Shubha Jain, F. Azam, Dr. H. N. Unni
We have developed and characterized a micro-fluidic mixer to study the macro-molecule dynamics such as kinetics of protein folding, DNA sequencing, single molecule study and detection etc. on a micro-second timescale. Numerical simulation has been performed to analyse the study of mixing performance of micro-fluidics channel.
|Assessing Diversity in Cassava through the Application of Metabolomics|
Margit Drapala, Elisabete Carvalhoa, Laura Perez-Fonsa, Elliott Pricea, L. Augusto Becerra Lopez-Lavalleb, Paul D. Frasera
In the present study metabolomic platforms have been established for Cassava and used to assess the biodiversity present in Cassava germplasm collections and elucidate underlying biochemical mechanisms associated with traits of interest.
|Building a digital pathology ecosystem for education and research|
Yves Sucaet, Silke Smeets, Stijn Piessens, Sabrina D'Haese, Chris Groven, Wim Waelput, Peter In't Veld
We wanted to build a core digital pathology infrastructure to support different use cases. Various images platforms needed to be accessible through a single access point, and support different user profiles. We wanted a scalable solution that would allow interaction between equipment from different research groups.
We built a centralized infrastructure that integrates a variety of imaging platforms, and now have an interconnected network of heterogeneous and scalable information silos.
|Design considerations for highly specific and efficient synthetic crRNA molecules|
Anja van Brabant Smith, Emily M. Anderson, Shawn McClelland, Elena Maksimova, Tyler Reed, Steve Lenger, Žaklina Strezoska, Hidevaldo Machado Dharmacon, part of GE Healthcare, 2650 Crescent Drive, Suite #100, Lafayette, CO 80026, US
An overview of our rational design algorithm for picking highly functional crRNA sequences in combination with comprehensive specificity analysis.